Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N02AX17
|
| gptkbp:CASNumber |
1206441-54-3
|
| gptkbp:drugClass |
opioid
|
| gptkbp:hasInChIKey |
QZQZQZQZQZQZQZ-QZQZQZQZSA-N
|
| gptkbp:hasMolecularFormula |
C22H30N2O2
|
| gptkbp:hasSMILES |
CC1=CC(=C(C=C1)O)C2(CCN(CC2)CC3=CC=CC=C3)C(=O)N
|
| gptkbp:hasUNII |
6Z5B6HVF6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
DB11709
|
| gptkbp:indication |
management of acute pain
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
Trevena Inc.
|
| gptkbp:mechanismOfAction |
mu-opioid receptor agonist
|
| gptkbp:molecularWeight |
354.49 g/mol
|
| gptkbp:name |
Oliceridine
|
| gptkbp:PubChem_CID |
gptkb:DB11709
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
true
|
| gptkbp:synonym |
TRV130
|
| gptkbp:bfsParent |
gptkb:SF-2281
|
| gptkbp:bfsLayer |
7
|